| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7173038 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Aug, 2021
(2 years ago) | |
| USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Jun, 2022
(1 year, 9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642608 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Feb, 2022
(2 years ago) | |
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(4 years from now) | |
Caprelsa is owned by Genzyme Corp.
Caprelsa contains Vandetanib.
Caprelsa has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Caprelsa are:
- US8642608
- US7173038
- USRE42353
Caprelsa was authorised for market use on 06 April, 2011.
Caprelsa is available in tablet;oral dosage forms.
Caprelsa can be used as for use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease.
Drug patent challenges can be filed against Caprelsa from 07 April, 2015.
The generics of Caprelsa are possible to be released after 08 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-9) | Apr 06, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 06, 2018 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
Drugs and Companies using VANDETANIB ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 06 April, 2011
Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease
Dosage: TABLET;ORAL
CAPRELSA family patents
